Spots Global Cancer Trial Database for Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
Official Title: Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
Study ID: NCT03096418
Conditions
Interventions
Study Description
Brief Summary: The hypothesis of this study is that paclitaxel levels increase chromosomal instability (CIN) in tumors and this is lethal to tumors that have pre-existing CIN. Treatment will be administered on an outpatient basis. Paclitaxel will be initiated as standard infusions on days 1, 8, and 15 of a 21-day cycle. Participants will continue with paclitaxel for cycles 2-4 prior to surgery.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Contact Details
Name: Mark Burkard
Affiliation: University of Wisconsin, Madison
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
